Bone-targeted nanocarrier systems in osteoporotic therapy: design strategies and therapeutic potential

Osteoporosis is characterized by reduced bone mineral density and deteriorated bone microarchitecture, and has become a growing global health challenge owing to increased fracture susceptibility. Despite diverse pharmacotherapeutic options, systemic toxicity, poor bioavailability, and patient non-compliance constrain clinical management. With the advent of nanomedicine, osteoporotic therapy is shifting from systemic drug exposure toward precise bone targeting. This review summarizes recent advances in bone-targeting nanocarrier systems. Literature within the past five years was identified through Scopus, Web of Science, Google Scholar, and PubMed using combinations of keywords including “Biomimetic Extracellular Vesicles,” “Bone Targeting nanocarrier,” “Bisphosphonates,” “Hydroxyapatite,” “Osteoporosis,” and “Stimuli-Responsive.” The review focuses on the pathophysiological basis for targeting and on active targeting strategies coupled with stimuli-responsive mechanisms triggered by the enzymatic and acidic bone microenvironment. It further discusses the potential of inorganic, lipid, and polymeric platforms for delivering bioactive compounds, nucleic acids, and small molecules, and scrutinizes critical barriers to clinical translation, including long-term biocompatibility, manufacturing scalability, and bone penetration depth. Collectively, this review highlights how the gap between therapeutic efficacy and safety of bone-targeting nanocarriers may be bridged, pointing toward the future of precision bone medicine. Osteoporosis weakens bones, making them fragile and easy to break. Currently, drugs that are used for treating osteoporosis have side effects because they can affect the whole body skeleton rather than specific bones. In the current literature review, a novel solution to this problem has been examined, namely, smart delivery systems referred to as nanocarriers. The main aim of this review is to show how these intelligent nanocarriers deliver therapeutic compounds to the desired target, that is, diseased bone tissues. Specifically, this review considers how such nanocarriers are made to recognize the diseased bone, how they deliver drugs only to the targeted tissue, and from which materials (fats or polymers) such devices are developed. In addition, the difficulties faced during translation from laboratory work to real-life clinics are discussed. Although it will probably take several more years of scientific studies before intelligent nanocarriers are available to everyone, we can say that this technology is a breakthrough one. Overall, the aim of such nanocarriers is to provide precision medicine for bones, meaning that in the near future, people can strengthen their bones safely.